Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936903 | 0.93 | MEN1 (0.36) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL1990955 | 0.93 | MEN1 (0.35) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL9935932 | 0.88 | MEN1 (0.33) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL9942771 | 0.87 | MEN1 (0.32) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL1983039 | 0.81 | MEN1 (0.30) | MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1989198 | 0.80 | — | — | |
| SCHEMBL15545048 | 0.78 | MAPT (0.41) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL2926247 | 0.74 | SMN1; SMN2 (0.45) | MEN1APAF1NPC1PLA2G1BHSP90AA1 | |
| SCHEMBL1987433 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL5474632 | 0.73 | NPC1 (0.44) | MEN1APAF1NPC1PLA2G1BHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509951-B1 | NOVEL CATIONIC AMINOPYRIDINES, DYE COMPOSITION COMPRISING A CATIONIC AMINOPYRIDINE, PROCESSES THEREFOR AND USES THEREOF | ORÉAL L (FR) | 2016-04-13 | — | — | EP | claimed |
| US-9220671-B2 | Dye composition comprising at least four dye precursors including at least one oxidation base and at least one coupler | L'OREAL (FR) | 2015-12-29 | — | — | US | claimed |
| US-8491669-B2 | Cationic 4-aminopyridine, dye composition comprising a cationic 4-aminopyridine, processes therefor and uses thereof | L'OREAL (FR) | 2013-07-23 | — | — | US | claimed |
| US-20130048007-A1 | NOVEL CATIONIC 4- AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | L'OREAL (FR) | 2013-02-28 | — | — | US | claimed |
| WO-2012080286-A9 | DYEING COMPOSITION COMPRISING A HETEROCYCLIC OXIDATION BASE AND A CATIONIC 3,5-DIAMINOPYRIDINE COUPLER | L'OREAL (FR) | 2013-01-31 | — | — | WO | claimed |
| EP-2509951-A1 | NOVEL CATIONIC AMINOPYRIDINES, DYE COMPOSITION COMPRISING A CATIONIC AMINOPYRIDINE, PROCESSES THEREFOR AND USES THEREOF | L'Oréal (FR) | 2012-10-17 | — | — | EP | claimed |
| WO-2012080286-A2 | DYEING COMPOSITION COMPRISING A HETEROCYCLIC OXIDATION BASE AND A CATIONIC 3,5-DIAMINOPYRIDINE COUPLER | L'OREAL (FR) | 2012-06-21 | — | — | WO | claimed |
| WO-2011069898-A1 | NOVEL CATIONIC AMINOPYRIDINES, DYE COMPOSITION COMPRISING A CATIONIC AMINOPYRIDINE, PROCESSES THEREFOR AND USES THEREOF | L'OREAL (FR) | 2011-06-16 | — | — | WO | claimed |
| WO-2016097022-A1 | DYE COMPOSITION COMPRISING A PARA-PHENYLENEDIAMINE OXIDATION BASE AND A PARTICULAR COUPLER | L'OREAL (FR) | 2016-06-23 | — | — | WO | disclosed |
| EP-2509951-B1 | NOVEL CATIONIC AMINOPYRIDINES, DYE COMPOSITION COMPRISING A CATIONIC AMINOPYRIDINE, PROCESSES THEREFOR AND USES THEREOF | ORÉAL L (FR) | 2016-04-13 | — | — | EP | disclosed |
| EP-2509951-B1 | NOVEL CATIONIC AMINOPYRIDINES, DYE COMPOSITION COMPRISING A CATIONIC AMINOPYRIDINE, PROCESSES THEREFOR AND USES THEREOF | ORÉAL L (FR) | 2016-04-13 | — | — | EP | disclosed |
| WO-2012080286-A9 | DYEING COMPOSITION COMPRISING A HETEROCYCLIC OXIDATION BASE AND A CATIONIC 3,5-DIAMINOPYRIDINE COUPLER | L'OREAL (FR) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012084472-A1 | PROCESS FOR DYEING KERATIN FIBRES USING HYDROXYBENZALDEHYDE DERIVATIVES, OXIDIZING AGENTS AND ALKALINIZING AGENTS IN THE PRESENCE OF HEAT | L'OREAL (FR) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012080286-A2 | DYEING COMPOSITION COMPRISING A HETEROCYCLIC OXIDATION BASE AND A CATIONIC 3,5-DIAMINOPYRIDINE COUPLER | L'OREAL (FR) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080289-A2 | DYE COMPOSITION COMPRISING AT LEAST FOUR DYE PRECURSORS INCLUDING AT LEAST ONE OXIDATION BASE AND AT LEAST ONE COUPLER | L'OREAL (FR) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080287-A2 | DYE COMPOSITION COMPRISING A SECONDARY PARA-PHENYLENEDIAMINE OXIDATION BASE AND A CATIONIC 3,5-DIAMINOPYRIDINE COUPLER | L'OREAL (FR) | 2012-06-21 | — | — | WO | disclosed |
| WO-2011069898-A1 | NOVEL CATIONIC AMINOPYRIDINES, DYE COMPOSITION COMPRISING A CATIONIC AMINOPYRIDINE, PROCESSES THEREFOR AND USES THEREOF | L'OREAL (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130048007-A1 | NOVEL CATIONIC 4- AMINOINDOLES, DYE COMPOSITION COMPRISING A CATIONIC 4-AMINOINDOLE, PROCESSES THEREFOR AND USES THEREOF | TPH1, ALDH7A1, FARS2 | MEN1 1266/4885APAF1 2120/4885NPC1 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.